Published in J Clin Oncol on June 01, 2000
Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov (2010) 4.66
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst (2009) 2.77
Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo. Br J Cancer (2013) 0.92
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer (2002) 0.89
Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. Ther Adv Med Oncol (2013) 0.87
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. J Exp Clin Cancer Res (2011) 0.83
Breast cancer (metastatic). BMJ Clin Evid (2007) 0.82
Styrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery - dual uptake through enterocytes and M-cells. Int J Nanomedicine (2015) 0.80
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) (2016) 0.79
Breast cancer (metastatic). BMJ Clin Evid (2010) 0.77
Kalanchoe tubiflora extract inhibits cell proliferation by affecting the mitotic apparatus. BMC Complement Altern Med (2012) 0.76
Human MAP Tau Based Targeted Cytolytic Fusion Proteins. Biomedicines (2017) 0.76
Depletion of enteric bacteria diminishes leukocyte infiltration following doxorubicin-induced small intestinal damage in mice. PLoS One (2017) 0.75
Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial. Contemp Oncol (Pozn) (2017) 0.75
CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo. Oncotarget (2016) 0.75
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer. Br J Cancer (2005) 0.75
Stilbene 5c, a microtubule poison with vascular disrupting properties that induces multiple modes of growth arrest and cell death. Biochem Pharmacol (2013) 0.75
The genome sequence of Schizosaccharomyces pombe. Nature (2002) 14.26
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Current concepts of the immunological function of the thymus. Physiol Rev (1967) 8.37
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
BioJava: an open-source framework for bioinformatics. Bioinformatics (2008) 6.17
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer (2000) 4.96
Body mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310 000 participants. Int J Epidemiol (2004) 4.67
KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell (1999) 4.52
Estrogen and the risk of breast cancer. N Engl J Med (2001) 4.39
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 4.24
Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens (2003) 3.67
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol (2005) 3.62
Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med (1997) 3.57
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Prelingual deafness: high prevalence of a 30delG mutation in the connexin 26 gene. Hum Mol Genet (1997) 3.26
Randomised studies of income supplementation: a lost opportunity to assess health outcomes. J Epidemiol Community Health (1999) 3.05
Txt2stop: a pilot randomised controlled trial of mobile phone-based smoking cessation support. Tob Control (2009) 3.05
Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst (1999) 2.99
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol (1999) 2.97
cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol (1992) 2.91
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
Anti-lymphocytic antibody--a review. Clin Exp Immunol (1967) 2.75
1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens (1999) 2.72
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70
Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res (2000) 2.65
Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol (2003) 2.57
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
Sodium channels SCN1A, SCN2A and SCN3A in familial autism. Mol Psychiatry (2003) 2.48
Kaposi's sarcoma in recipients of renal transplants. Am J Med (1979) 2.45
BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38
The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care (2003) 2.36
The International Clinical Epidemiology Network (INCLEN): a progress report. J Clin Epidemiol (1991) 2.32
Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol (1999) 2.29
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health (2007) 2.25
Human monoclonal antibody production. Current status and future prospects. J Immunol Methods (1987) 2.21
Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. Int J Epidemiol (2005) 2.16
Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res (1994) 2.11
A novel deletion involving the connexin-30 gene, del(GJB6-d13s1854), found in trans with mutations in the GJB2 gene (connexin-26) in subjects with DFNB1 non-syndromic hearing impairment. J Med Genet (2005) 2.11
Randomized clinical trial of honey-impregnated dressings for venous leg ulcers. Br J Surg (2008) 2.08
Laboratory staff qualifications and accuracy of proficiency test results. A national study. Arch Pathol Lab Med (1992) 2.07
The hopelessness scale for children: psychometric characteristics and concurrent validity. J Consult Clin Psychol (1986) 2.06
Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci U S A (2008) 2.06
The natural history of Peyronie's disease. J Urol (1990) 2.02
Clinical features of the prevalent form of childhood deafness, DFNB1, due to a connexin-26 gene defect: implications for genetic counselling. Lancet (1999) 2.00
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback. J Clin Oncol (1998) 1.97
beta ig-h3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol (1994) 1.97
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol (1994) 1.97
Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol (1999) 1.96
Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol (1988) 1.93
Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol (1999) 1.92
Emergency response to raccoon rabies introduction into Ontario. J Wildl Dis (2001) 1.91
Effect of antilymphocytic antibody and antibody fragments on human lymphocytes in vitro. Nature (1967) 1.89
Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer (1997) 1.85
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
The effects of thymus and other lymphoid organs enclosed in millipore diffusion chambers on neonatally thymectomized mice. J Exp Med (1965) 1.78
Psychotic men remanded in custody to Brixton Prison. Br J Psychiatry (1994) 1.77
Renal cryosurgery: experimental evaluation of treatment parameters. Urology (1998) 1.76
Survey of the frequency of USH1 gene mutations in a cohort of Usher patients shows the importance of cadherin 23 and protocadherin 15 genes and establishes a detection rate of above 90%. J Med Genet (2006) 1.72
Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. Br Med J (Clin Res Ed) (1983) 1.72
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Human T-cell leukaemia/lymphoma virus-associated lymphoreticular neoplasia in Jamaica. Lancet (1983) 1.69
Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer (1999) 1.68
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol (2011) 1.64
A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat (2009) 1.63
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
Presentation of poisoned patients to accident and emergency departments in the north of England. Hum Exp Toxicol (1996) 1.61
Avoiding interpretive pitfalls when assessing arrhythmia suppression after myocardial infarction: insights from the long-term observations of the placebo-treated patients in the Cardiac Arrhythmia Pilot Study (CAPS) J Am Coll Cardiol (1991) 1.60
Predictors and moderators of response to internet-delivered Interpersonal Psychotherapy and Cognitive Behavior Therapy for depression. J Affect Disord (2013) 1.59
Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res (1996) 1.58
A genomewide suppressor and enhancer analysis of cdc13-1 reveals varied cellular processes influencing telomere capping in Saccharomyces cerevisiae. Genetics (2008) 1.58
Hypertension--time to move on. Lancet (2005) 1.57
Characterization and expression of a spliced leader RNA in the parasitic nematode Ascaris lumbricoides var. suum. Mol Cell Biol (1989) 1.57
RPGR is mutated in patients with a complex X linked phenotype combining primary ciliary dyskinesia and retinitis pigmentosa. J Med Genet (2005) 1.56
Loss-of-function and residual channel activity of connexin26 mutations associated with non-syndromic deafness. FEBS Lett (2003) 1.56
Restriction of the capacity to respond to two antigens by single precursors of antibody-producing cells in culture. J Exp Med (1969) 1.55
Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg (1992) 1.55
Quality-of-life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst (1992) 1.55
Some physical and radiobiological properties of immunologically reactive mouse spleen cells. J Exp Med (1970) 1.55
Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res (1997) 1.54